Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour: does it increase the risk for tumour cell seeding and recurrence?
Purpose - Preoperative percutaneous transabdominal wall biopsy may be considered to diagnose gastrointestinal stromal tumour (GIST) and plan preoperative treatment with tyrosine kinase inhibitors when an endoscopic biopsy is not possible. Hypothetically, a transabdominal wall biopsy might lead to ce...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
28 March 2016
|
| In: |
European journal of cancer
Year: 2016, Volume: 59, Pages: 128-133 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2016.02.021 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.ejca.2016.02.021 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001386 
|
| Author Notes: | Mikael Eriksson, Peter Reichardt, Kirsten Sundby Hall, Jochen Schütte, Silke Cameron, Peter Hohenberger, Sebastian Bauer, Mika Leinonen, Annette Reichardt, Maria Rejmyr Davis, Thor Alvegård, Heikki Joensuu |
| Summary: | Purpose - Preoperative percutaneous transabdominal wall biopsy may be considered to diagnose gastrointestinal stromal tumour (GIST) and plan preoperative treatment with tyrosine kinase inhibitors when an endoscopic biopsy is not possible. Hypothetically, a transabdominal wall biopsy might lead to cell seeding and conversion of a local GIST to a disseminated one. We investigated the influence of preoperative needle biopsy on survival outcomes. - Methods - We collected the clinical data from hospital case records of the 397 patients who participated in the Scandinavian Sarcoma Group (SSG) XVIII/Arbeitsgemeinschaft Internistische Onkologie (AIO) randomised trial and who had a transabdominal fine needle and/or core needle biopsy carried out prior to study entry. The SSG XVIII/AIO trial compared 1 and 3 years of adjuvant imatinib in a patient population with a high risk of GIST recurrence after macroscopically radical surgery. The primary end-point was recurrence-free survival (RFS), and the secondary end-points included overall survival (OS). - Results - A total of 47 (12.0%) out of the 393 patients with data available underwent a percutaneous biopsy. No significant difference in RFS or OS was found between the patients who underwent or did not undergo a percutaneous biopsy either in the entire series or in subpopulation analyses, except for a statistically significant RFS advantage for patients who had a percutaneous biopsy and a tumour ≥10 cm in diameter. - Conclusion - A preoperative diagnostic percutaneous biopsy of a suspected GIST may not increase the risk for GIST recurrence in a patient population who receive adjuvant imatinib after the biopsy. |
|---|---|
| Item Description: | Gesehen am 07.11.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2016.02.021 |